Literature DB >> 27075659

Phase I-II Clinical Trial Assessing Safety and Efficacy of Umbilical Cord Blood Mononuclear Cell Transplant Therapy of Chronic Complete Spinal Cord Injury.

Hui Zhu1,2, Waisang Poon3, Yansheng Liu1,2, Gilberto Ka-Kit Leung4, Yatwa Wong4, Yaping Feng1, Stephanie C P Ng3, Kam Sze Tsang3, David T F Sun3, David K Yeung3, Caihong Shen1,2, Fang Niu1,2, Zhexi Xu1,2, Pengju Tan1,2, Shaofeng Tang1, Hongkun Gao1,2, Yun Cha1, Kwok-Fai So5,6,7, Robert Fleischaker8, Dongming Sun9, John Chen7, Jan Lai7, Wendy Cheng7, Wise Young7,9.   

Abstract

Umbilical cord blood-derived mononuclear cell (UCB-MNC) transplants improve recovery in animal spinal cord injury (SCI) models. We transplanted UCB-MNCs into 28 patients with chronic complete SCI in Hong Kong (HK) and Kunming (KM). Stemcyte Inc. donated UCB-MNCs isolated from human leukocyte antigen (HLA ≥4:6)-matched UCB units. In HK, four patients received four 4-μl injections (1.6 million cells) into dorsal entry zones above and below the injury site, and another four received 8-μl injections (3.2 million cells). The eight patients were an average of 13 years after C5-T10 SCI. Magnetic resonance diffusion tensor imaging of five patients showed white matter gaps at the injury site before treatment. Two patients had fiber bundles growing across the injury site by 12 months, and the rest had narrower white matter gaps. Motor, walking index of SCI (WISCI), and spinal cord independence measure (SCIM) scores did not change. In KM, five groups of four patients received four 4-μl (1.6 million cells), 8-μl (3.2 million cells), 16-μl injections (6.4 million cells), 6.4 million cells plus 30 mg/kg methylprednisolone (MP), or 6.4 million cells plus MP and a 6-week course of oral lithium carbonate (750 mg/day). KM patients averaged 7 years after C3-T11 SCI and received 3-6 months of intensive locomotor training. Before surgery, only two patients walked 10 m with assistance and did not need assistance for bladder or bowel management before surgery. The rest could not walk or do their bladder and bowel management without assistance. At about a year (41-87 weeks), WISCI and SCIM scores improved: 15/20 patients walked 10 m ( p = 0.001) and 12/20 did not need assistance for bladder management ( p = 0.001) or bowel management ( p = 0.002). Five patients converted from complete to incomplete (two sensory, three motor; p = 0.038) SCI. We conclude that UCB-MNC transplants and locomotor training improved WISCI and SCIM scores. We propose further clinical trials.

Entities:  

Keywords:  Central pattern generator; Lithium; Mononuclear cells; Spinal cord injury (SCI); Umbilical cord blood

Mesh:

Substances:

Year:  2016        PMID: 27075659     DOI: 10.3727/096368916X691411

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  31 in total

1.  Clinical Study of NeuroRegen Scaffold Combined With Human Mesenchymal Stem Cells for the Repair of Chronic Complete Spinal Cord Injury.

Authors:  Yannan Zhao; Fengwu Tang; Zhifeng Xiao; Guang Han; Nuo Wang; Na Yin; Bing Chen; Xianfeng Jiang; Chen Yun; Wanjun Han; Changyu Zhao; Shixiang Cheng; Sai Zhang; Jianwu Dai
Journal:  Cell Transplant       Date:  2017-02-09       Impact factor: 4.064

2.  Curcumin Improves Human Umbilical Cord-Derived Mesenchymal Stem Cell Survival via ERK1/2 Signaling and Promotes Motor Outcomes After Spinal Cord Injury.

Authors:  Wu Wanjiang; Chen Xin; Chen Yaxing; Wang Jie; Zhang Hongyan; Ni Fei; Ling Chengmin; Feng Chengjian; Yuan Jichao; Lin Jiangkai
Journal:  Cell Mol Neurobiol       Date:  2020-11-27       Impact factor: 5.046

3.  Long-term safety evaluation of placental mesenchymal stromal cells for in utero repair of myelomeningocele in a novel ovine model.

Authors:  Sarah C Stokes; Christina M Theodorou; Jordan E Jackson; Christopher Pivetti; Priyadarsini Kumar; Kaeli J Yamashiro; Zachary J Paxton; Lizette Reynaga; Alicia Hyllen; Aijun Wang; Diana L Farmer
Journal:  J Pediatr Surg       Date:  2021-09-20       Impact factor: 2.549

Review 4.  Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies.

Authors:  Luisa R Galieva; Yana O Mukhamedshina; Svetlana S Arkhipova; Albert A Rizvanov
Journal:  Front Pharmacol       Date:  2017-09-08       Impact factor: 5.810

5.  Electrophysiological, Morphological, and Ultrastructural Features of the Injured Spinal Cord Tissue after Transplantation of Human Umbilical Cord Blood Mononuclear Cells Genetically Modified with the VEGF and GDNF Genes.

Authors:  Y O Mukhamedshina; Z E Gilazieva; S S Arkhipova; L R Galieva; E E Garanina; A A Shulman; G G Yafarova; Y A Chelyshev; N V Shamsutdinova; A A Rizvanov
Journal:  Neural Plast       Date:  2017-03-21       Impact factor: 3.599

6.  Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017).

Authors:  Hongyun Huang; Wise Young; Lin Chen; Shiqing Feng; Ziad M Al Zoubi; Hari Shanker Sharma; Hooshang Saberi; Gustavo A Moviglia; Xijing He; Dafin F Muresanu; Alok Sharma; Ali Otom; Russell J Andrews; Adeeb Al-Zoubi; Andrey S Bryukhovetskiy; Elena R Chernykh; Krystyna Domańska-Janik; Emad Jafar; W Eustace Johnson; Ying Li; Daqing Li; Zuo Luan; Gengsheng Mao; Ashok K Shetty; Dario Siniscalco; Stephen Skaper; Tiansheng Sun; Yunliang Wang; Lars Wiklund; Qun Xue; Si-Wei You; Zuncheng Zheng; Milan R Dimitrijevic; W S El Masri; Paul R Sanberg; Qunyuan Xu; Guoming Luan; Michael Chopp; Kyoung-Suok Cho; Xin-Fu Zhou; Ping Wu; Kai Liu; Hamid Mobasheri; Seiji Ohtori; Hiroyuki Tanaka; Fabin Han; Yaping Feng; Shaocheng Zhang; Yingjie Lu; Zhicheng Zhang; Yaojian Rao; Zhouping Tang; Haitao Xi; Liang Wu; Shunji Shen; Mengzhou Xue; Guanghong Xiang; Xiaoling Guo; Xiaofeng Yang; Yujun Hao; Yong Hu; Jinfeng Li; Qiang Ao; Bin Wang; Zhiwen Zhang; Ming Lu; Tong Li
Journal:  Cell Transplant       Date:  2018-02       Impact factor: 4.064

Review 7.  Translational Regenerative Therapies for Chronic Spinal Cord Injury.

Authors:  Kyriakos Dalamagkas; Magdalini Tsintou; Amelia Seifalian; Alexander M Seifalian
Journal:  Int J Mol Sci       Date:  2018-06-15       Impact factor: 5.923

Review 8.  Cell therapy and delivery strategies for spinal cord injury.

Authors:  Bruna Dos S Ramalho; Fernanda M de Almeida; Ana M B Martinez
Journal:  Histol Histopathol       Date:  2021-06-10       Impact factor: 2.303

9.  Combination of epidural electrical stimulation with ex vivo triple gene therapy for spinal cord injury: a proof of principle study.

Authors:  Filip Olegovich Fadeev; Farid Vagizovich Bashirov; Vahe Arshaluysovich Markosyan; Andrey Alexandrovich Izmailov; Tatyana Vyacheslavovna Povysheva; Mikhail Evgenyevich Sokolov; Maxim Sergeevich Kuznetsov; Anton Alexandrovich Eremeev; Ilnur Ildusovich Salafutdinov; Albert Anatolyevich Rizvanov; Hyun Joon Lee; Rustem Robertovich Islamov
Journal:  Neural Regen Res       Date:  2021-03       Impact factor: 5.135

10.  A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children With Cerebral Palsy.

Authors:  Li Huang; Che Zhang; Jiaowei Gu; Wei Wu; Zhujun Shen; Xihui Zhou; Haixia Lu
Journal:  Cell Transplant       Date:  2018-02       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.